If you or a loved one is taking Tysabri and experiencing new neurological symptoms such as confusion, vision changes, or weakness on one side of the body, it's natural to be concerned about progressive multifocal leukoencephalopathy (PML). The medical community has built a robust framework for identifying and managing this rare but serious condition. This page explains the symptom patterns and diagnostic steps that clinicians use to evaluate PML risk in Tysabri patients.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The following narrative synthesizes evidence from FDA-approved labeling to describe the clinical presentation, pharmacological context, mechanistic links, and risk considerations relevant to patients and settlement criteria. Progressive multifocal leukoencephalopathy is an opportunistic viral infection of the brain caused by the JC virus that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation often includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and speech difficulties. Diagnosis relies on brain imaging, typically MRI showing demyelinating lesions, and detection of JC virus DNA in cerebrospinal fluid. The condition is frequently fatal or results in permanent disability. Tysabri is a monoclonal antibody that binds to alpha-4 integrin, inhibiting leukocyte adhesion and migration into the central nervous system. This mechanism reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance against JC virus, allowing reactivation and spread in the brain. The FDA-approved label explicitly states that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration especially beyond two years, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy.
In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 multiple sclerosis patients treated for a median of 120 weeks; both had received Tysabri in addition to interferon beta-1a. The third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These data underscore that PML risk is present even in monotherapy but may be elevated with prior immunosuppressant use. The adequacy of warnings regarding Tysabri and PML is addressed by the boxed warning, which states that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These measures indicate that the manufacturer and FDA have implemented risk mitigation strategies, but the adequacy of warnings in individual cases may be subject to legal evaluation.
Settlement-related considerations for affected patients typically involve demonstrating that PML developed as a direct consequence of Tysabri therapy, that the patient was not adequately warned of the risk, and that the harm resulted in severe disability or death. The timeline between exposure and documented harm is critical. PML can occur after varying durations of treatment; in clinical trials, cases were observed after approximately 120 weeks in MS patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label notes that longer treatment duration, especially beyond two years, increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who develop PML after shorter exposure may have additional risk factors such as anti-JCV antibodies or prior immunosuppressant use. In summary, the evidence establishes a clear mechanistic link between Tysabri and PML, with known risk factors and a documented timeline of harm. The FDA-approved warnings are explicit, but the severity of PML and its often fatal or disabling outcome form the basis for legal claims. Settlement criteria typically require proof of Tysabri use, PML diagnosis, and evidence that the patient was not adequately informed of the risk or that the risk was not properly managed.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) increases the risk of PML, a severe opportunistic brain infection caused by the JC virus. The FDA-approved label includes a boxed warning stating that Tysabri increases the risk of PML, which usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three established risk factors are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Settlement criteria generally require proof of Tysabri use, a confirmed PML diagnosis, and evidence that the patient was not adequately warned of the risk or that the risk was not properly managed. The timeline between exposure and harm is critical.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.